- The Wall Street Journal•2 months ago
Zymeworks Inc. has formed its seventh corporate alliance, a deal with Daiichi Sankyo Co. that deepens its pipeline of potential cancer therapeutics.
- Zacks•5 months ago
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
D4S.F : Summary for DAIICHI SANKYO CO. LTD - Yahoo Finance
Daiichi Sankyo Company, Limited (D4S.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
|Bid||19.33 x 50000|
|Ask||19.91 x 50000|
|Day's Range||19.75 - 19.75|
|52 Week Range||16.57 - 23.15|
|PE Ratio (TTM)||25.23|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|